☰

Kyle R. Crassini, MBBS, PhD - Publications

Affiliations: 
2019 Faculty of Medicine and Health University of Sydney, Camperdown, New South Wales, Australia 
Area:
Haematology, Molecular genetics
Tree Info Grants Similar researchers PubMed Report error

28 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Fatima N, Shen Y, Crassini K, Burling O, Thurgood L, Iwanowicz EJ, Lang H, Karanewsky DS, Christopherson RI, Mulligan SP, Best OG. The CIpP activator, TR-57, is highly effective as a single agent and in combination with venetoclax against CLL cells . Leukemia & Lymphoma. 1-13. PMID 38227293 DOI: 10.1080/10428194.2023.2300055  0.763
2023 Crassini K, Gibson J. Pathogenesis and management of immune dysfunction secondary to B cell haematological malignancies. Internal Medicine Journal. PMID 38066723 DOI: 10.1111/imj.16279  0.324
2023 Anderson MA, Bennett R, Badoux X, Best G, Chia N, Cochrane T, Cull G, Crassini K, Harrup R, Jackson S, Kuss B, Lasica M, Lew TE, Marlton P, Opat S, et al. Chronic lymphocytic leukaemia Australasian consensus practice statement. Internal Medicine Journal. 53: 1678-1691. PMID 37743239 DOI: 10.1111/imj.16207  0.612
2021 Fatima N, Shen Y, Crassini K, Iwanowicz EJ, Lang H, Karanewsky DS, Christopherson RI, Mulligan SP, Best OG. The ClpP activator ONC-212 (TR-31) inhibits BCL2 and B-cell receptor signaling in CLL. Ejhaem. 2: 81-93. PMID 35846080 DOI: 10.1002/jha2.160  0.802
2020 Fatima N, Crassini KR, Thurgood L, Shen Y, Christopherson RI, Kuss B, Mulligan SP, Best OG. Therapeutic approaches and drug-resistance in chronic lymphocytic leukaemia. Cancer Drug Resistance (Alhambra, Calif.). 3: 532-549. PMID 35582439 DOI: 10.20517/cdr.2019.111  0.74
2020 Shen Y, Crassini K, Fatima N, O'Dwyer M, O'Neill M, Christopherson RI, Mulligan SP, Best OG. IBL-202 is synergistic with venetoclax in CLL under in vitro conditions that mimic the tumor microenvironment. Blood Advances. 4: 5093-5106. PMID 33085757 DOI: 10.1182/bloodadvances.2019001369  0.799
2019 Crassini K, Stevenson WS, Mulligan SP, Best OG. Molecular pathogenesis of chronic lymphocytic leukaemia. British Journal of Haematology. PMID 31364161 DOI: 10.1111/Bjh.16102  0.743
2019 Shen Y, Crassini K, Sandhu S, Fatima N, Christopherson RI, Mulligan SP, Best OG. Dual inhibition of MEK1/2 and AKT by binimetinib and MK2206 induces apoptosis of chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment. Leukemia & Lymphoma. 1-12. PMID 30648436 DOI: 10.1080/10428194.2018.1542148  0.807
2019 Fatima N, Shen Y, Crassini KR, Iwanowicz E, Christopherson R, Best G, Mulligan SP. TR57, an Inhibitor of the Integrated Stress Response, Is Synergistic with Venetoclax Against CLL Cells, Independent of Their TP53 Status Blood. 134: 1735-1735. DOI: 10.1182/Blood-2019-132160  0.737
2019 Shen Y, Crassini KR, Fatima N, Christopherson R, Mulligan SP, Best OG. Venetoclax Is Synergistic with Idelalisib or MK2206 Against Primary CLL Cells in an in Vitro Model of the Microenvironment Blood. 134: 5443-5443. DOI: 10.1182/Blood-2019-130082  0.81
2018 Crassini K, Shen Y, O'Dwyer M, O'Neill M, Christopherson R, Mulligan S, Best OG. The dual inhibitor of the phosphoinositol-3 and PIM kinases, IBL-202, is effective against chronic lymphocytic leukaemia cells under conditions that mimic the hypoxic tumour microenvironment. British Journal of Haematology. PMID 29978459 DOI: 10.1111/Bjh.15447  0.809
2018 Crassini KR, Best OG, Mulligan SP. Immune failure, infection and survival in chronic lymphocytic leukemia. Haematologica. 103: e329. PMID 29970494 DOI: 10.3324/Haematol.2018.196543  0.698
2018 Crassini K, Pyke T, Shen Y, Stevenson WS, Christopherson RI, Mulligan SP, Best OG. Inhibition of the Raf-1 kinase inhibitory protein (RKIP) by locostatin induces cell death and reduces the CXCR4-mediated migration of chronic lymphocytic leukemia cells. Leukemia & Lymphoma. 1-12. PMID 29911936 DOI: 10.1080/10428194.2018.1455974  0.811
2018 Crassini K, Shen Y, Stevenson WS, Christopherson R, Ward C, Mulligan SP, Best OG. MEK1/2 inhibition by binimetinib is effective as a single agent and potentiates the actions of Venetoclax and ABT-737 under conditions that mimic the chronic lymphocytic leukaemia (CLL) tumour microenvironment. British Journal of Haematology. PMID 29767411 DOI: 10.1111/Bjh.15282  0.823
2018 Crassini KR, Zhang E, Balendran S, Freeman JA, Best OG, Forsyth CJ, Mackinlay NJ, Han P, Stevenson WS, Mulligan SP. Humoral immune failure defined by immunoglobulin class and immunoglobulin G subclass deficiency is associated with shorter treatment-free and overall survival in Chronic Lymphocytic Leukaemia. British Journal of Haematology. PMID 29468645 DOI: 10.1111/Bjh.15146  0.727
2018 Crassini KR, Shen Y, Stevenson WS, Mulligan SP, Best OG, Christopherson R. mRNA Profiling of CLL Cells Derived from the Blood, Bone Marrow and Lymph Node Blood. 132: 1850-1850. DOI: 10.1182/Blood-2018-99-118264  0.745
2018 Shen Y, Crassini KR, O'Dwyer ME, O'Neill MF, Christopherson R, Mulligan SP, Best OG. The Dual PI3/PIM-Kinase Inhibitor, Ibl-202, Is Highly Synergistic with Venetoclax Against CLL Cells, and TP53-Knock-out Cells, and Under Conditions That Mimic the Tumor Microenvironment Blood. 132: 1870-1870. DOI: 10.1182/Blood-2018-99-115574  0.805
2018 Rizwan N, Shen Y, Iwanowicz E, Mulligan SP, Crassini KR, Christopherson R, Best OG. ONC-212 (I-39), a Novel Inhibitor of the UPR, Is Cytotoxic and Cytostatic Against CLL Cells Under in Vitro Conditions That Mimic the Tumor Microenvironment Blood. 132: 3145-3145. DOI: 10.1182/Blood-2018-99-115555  0.798
2016 Crassini K, Shen Y, Mulligan S, Giles Best O. Modeling the chronic lymphocytic leukemia microenvironment in vitro. Leukemia & Lymphoma. 1-14. PMID 27756161 DOI: 10.1080/10428194.2016.1204654  0.668
2015 Crassini K, Mulligan SP, Best OG. Targeting chronic lymphocytic leukemia cells in the tumor microenviroment: A review of the in vitro and clinical trials to date. World Journal of Clinical Cases. 3: 694-704. PMID 26301230 DOI: 10.12998/Wjcc.V3.I8.694  0.794
2015 Crassini K, Stevenson WS, Mulligan SP, Best OG. The MEK1/2 inhibitor, MEKi-1, induces cell death in Chronic Lymphocytic Leukemia cells under conditions that mimic the tumor microenvironment and is synergistic with fludarabine. Leukemia & Lymphoma. 1-29. PMID 25804768 DOI: 10.3109/10428194.2015.1032963  0.804
2014 Best OG, Crassini K, O'Neill M, O'Dwyer ME, Mulligan SP. Dual Inhibition of PIM and PI3-Kinase By Ibl-202 Is Highly Synergistic Compared to Mono-Molecular Inhibition and Represents a Novel Treatment Strategy for Chronic Lymphocytic Leukemia Blood. 124: 4693-4693. DOI: 10.1182/Blood.V124.21.4693.4693  0.795
2014 Crassini K, Stevenson WS, Mulligan SP, Best OG. MEK1/2 Inhibition By MEK162 Is Effective Against Chronic Lymphocytic Leukaemia Cells Under Conditions That Mimic Stimulation of B-Cell Receptor-Mediated Signaling Blood. 124: 3330-3330. DOI: 10.1182/Blood.V124.21.3330.3330  0.808
2014 Best OG, Pyke T, Crassini K, Stevenson WS, Mulligan SP. The Oxazolidinone Derivative Locostatin Induces Apoptosis in CLL Cells through Inhibition of AKT and MAPK-ERK1/2 Signaling Under Conditions That Mimic the Tumor Microenvironment Blood. 124: 3326-3326. DOI: 10.1182/Blood.V124.21.3326.3326  0.808
2013 Best OG, Crassini K, Freeman JA, Mulligan SP. The clinical significance of hypogammaglobulinaemia and serum immunoglobulin G subclass deficiency in patients with chronic lymphocytic leukaemia (CLL). Scandinavian Journal of Infectious Diseases. 45: 729. PMID 23826794 DOI: 10.3109/00365548.2013.809477  0.702
2013 Freeman JA, Crassini KR, Best OG, Forsyth CJ, Mackinlay NJ, Han P, Stevenson W, Mulligan SP. Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia. Leukemia & Lymphoma. 54: 99-104. PMID 22738394 DOI: 10.3109/10428194.2012.706285  0.708
2013 Crassini K, Stevenson Ws, Mulligan SP, Frcpa. MAPK-Erk1/2 Pathway Activation and Survival Of Chronic Lymphocytic Leukemia (CLL) Cells Is Induced By In Vitro Modeling Of The Tumor Microenvironment and Can Be Effectively Inhibited Using The MEK1 Inhibitor MEK162 Blood. 122: 4192-4192. DOI: 10.1182/Blood.V122.21.4192.4192  0.748
2012 Best G, Crassini K, Stevenson W, Mulligan SP. Inhibition of Mitogen Activated Protein Kinase Kinase (MEK1) Is Effective Against CLL Cells Cultured in Media Alone or in a Supportive Microenvironment and Is Synergistic with Fludarabine in a Mechanism That Involves Decreased Levels of Reactive Oxygen Species and MCL-1 Protein Blood. 120: 1804-1804. DOI: 10.1182/Blood.V120.21.1804.1804  0.748
Show low-probability matches.